![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 23, 2010 12:48:08 PM
Abbott stent tops Boston Sci's at two years -study - Reuters, 4:34:00 AM
Boston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Date : 09/22/2010 @ 1:01PM
Source : PR Newswire
Stock : Boston Scientific (BSX)
Quote : 5.585 -0.035 (-0.62%) @ 12:31PM
Boston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Boston Scientific (NYSE:BSX)
Intraday Stock Chart
Today : Thursday 23 September 2010
Click Here for more Boston Scientific Charts.
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients. Analysis of the data was presented by Louis A. Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Michigan, and Co-Principal Investigator of the PERSEUS clinical program, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.
"The PERSEUS diabetic subset data showed that the TAXUS Element Stent mitigated the impact of diabetes as a risk factor for restenosis following stenting procedures in the patients studied," said Dr. Cannon. "At one year, no significant differences in measures of stent efficacy were observed between the two patient groups. Diabetic status was not a predictor of re-intervention in patients treated with the TAXUS Element Stent."
The PERSEUS diabetic analysis included clinical outcomes at one year among 314 diabetic patients and 852 non-diabetic patients treated with the TAXUS Element Stent from the PERSEUS Workhorse and Small Vessel clinical trials. Due to significant disparity in baseline characteristics between diabetic and non-diabetic patients, propensity score analysis was used to allow for adjustment of baseline differences (other than the presence of diabetes) between the two groups.
Results showed that the TAXUS Element Stent maintained comparable rates of TLR at one year, whether adjusted or unadjusted, in the diabetic and non-diabetic patient populations (5.5 percent vs. 4.1 percent, p=0.43, adjusted). The adjusted and unadjusted rates of target lesion failure (TLF) at one year (defined as ischemia-driven TLR, or MI/cardiac death related to the target vessel) were also similar between the patient groups (7.5 percent vs. 5.4 percent, p=0.31, adjusted). Adjusted one-year rates of MACE, cardiac death, MI and ARC(1) definite/probable stent thrombosis showed no differences between the two populations (p-values of 0.14, 0.12, 0.38, and 0.77, respectively).
Nine-month adjusted angiographic outcomes showed similar in-segment late loss in diabetics and non-diabetics (0.23 mm vs. 0.19 mm, p=0.52). Rates of late loss for the TAXUS Element Stent were numerically lower than rates in prior studies for the TAXUS Express® and TAXUS Liberte® Stents(2).
"The PERSEUS diabetic analysis reinforces the historically consistent performance of paclitaxel in diabetic patients compared to non-diabetic patients," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group. "The paclitaxel-based TAXUS Element Stent has a unique mechanism of action that helps inhibit restenosis across a wide variety of patients with coronary artery disease."
The TAXUS Element Stent leverages the performance advantages of the Element platform with a decade of clinical success from the TAXUS program. The novel stent architecture and proprietary platinum chromium alloy combine to offer greater radial strength and flexibility. The stent architecture helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system. The higher density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents(3).
"We are pleased to see the strong performance of the TAXUS Element Stent in both the overall population of the PERSEUS trial and the diabetic patient subset," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "As the worldwide prevalence of diabetes continues to increase dramatically, these findings are very encouraging for physicians and their patients."
Diabetes is generally associated with an increased risk of cardiovascular events and patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting.
In March, the Company announced one-year results from its PERSEUS clinical program demonstrating positive safety and efficacy outcomes for the TAXUS Element Stent System compared to prior-generation Boston Scientific stents in more than 1,486 patients in two parallel trials at 90 centers worldwide.
The TAXUS Element Paclitaxel-Eluting Stent System received CE Mark approval in May, which included a specific indication for the treatment of diabetic patients. The Company received CE Mark approval for the PROMUS® Element™ Everolimus-Eluting Stent System in October 2009. Both Element systems incorporate the same platinum chromium alloy, innovative stent design and advanced catheter delivery system.
The Company expects U.S. Food and Drug Administration approval for the TAXUS Element Stent System(4) in mid 2011 and for the PROMUS Element Stent System in mid 2012. In Japan, the Company expects approval for the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS Element Stent System in mid 2012.
In the U.S., the TAXUS Element (ION) Stent and the PROMUS Element Stent are investigational devices and are limited by applicable law to investigational use only and are not available for sale.
Recent BSX News
- Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results • PR Newswire (US) • 07/01/2024 12:00:00 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Silk Road Medical, Inc. • PR Newswire (US) • 06/18/2024 05:23:00 PM
- Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc. • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints • PR Newswire (US) • 05/18/2024 03:03:00 PM
- Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors • PR Newswire (US) • 05/08/2024 08:00:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Boston Scientific Announces Results for First Quarter 2024 • PR Newswire (US) • 04/24/2024 10:30:00 AM
- Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module • PR Newswire (US) • 04/08/2024 04:00:00 AM
- Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon • PR Newswire (US) • 03/01/2024 11:55:00 AM
- Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes • PR Newswire (US) • 02/27/2024 09:15:00 PM
- Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes • PR Newswire (US) • 02/23/2024 02:27:00 AM
- Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/05/2024 01:00:00 PM
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023 • PR Newswire (US) • 01/31/2024 11:30:00 AM
- U.S. Futures Waver Ahead of Fed Decision Amid Mixed Corporate Earnings; Oil Prices Slide • IH Market News • 01/31/2024 11:29:30 AM
- Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System • PR Newswire (US) • 01/31/2024 11:25:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc. • PR Newswire (US) • 01/08/2024 09:55:00 PM
- Axonics Shares Climb 20% After Acquisition by Boston Scientific • Dow Jones News • 01/08/2024 04:36:00 PM
- Boston Scientific To Acquire Axonics For About $3.7 Billion • Dow Jones News • 01/08/2024 12:41:00 PM
- Axonics Announces Definitive Agreement to be Acquired by Boston Scientific • Business Wire • 01/08/2024 12:00:00 PM
- Boston Scientific Announces Agreement to Acquire Axonics, Inc. • PR Newswire (US) • 01/08/2024 12:00:00 PM
- Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation • PR Newswire (US) • 12/28/2023 09:00:00 PM
- Boston Scientific Closes Acquisition of Relievant Medsystems, Inc. • PR Newswire (US) • 11/17/2023 02:00:00 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM